CClinicalTrials.gg
Not yet recruitingNCT07032701Updated Jul 1, 2026

A Disposable Negative Pressure Wound Therapy Device (SNaP) to Promote Wound Healing in the Lower Limbs Following Mohs Micrographic Surgery for Non-melanoma Skin Cancer

An interventional study of Best Practice and Educational Intervention in Skin Carcinoma, sponsored by Jonsson Comprehensive Cancer Center. Not yet recruiting at 1 site in United States. Open to participants aged 19 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Jonsson Comprehensive Cancer Center · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
19 Years to 79 Years
Sex
All
01

Study summary

This clinical trial studies whether a disposable negative pressure wound therapy (dNPWT) device, SNaP Wound Care System (Ultraportable Mechanically Powered Negative Pressure Wound Therapy) (SNaP), promotes wound healing in the lower limbs in patients that have undergone Mohs micrographic surgery (Mohs surgery) for non-melanoma skin cancer. Mohs surgery is a surgical technique used to treat skin cancer. Individual layers of cancerous tissue are removed and examined under a microscope one at a time until all cancerous tissue has been removed. It is an important part of removing skin cancer, but it often leads to soft-tissue defects and reconstructive challenges, especially in high-tension areas like the lower limbs. Typically, these wounds are managed by leaving them open and allowing them to heal from the base up or are reconstructed by transferring healthy skin from another part of the body. Negative pressure wound therapy (NPWT) is a wound dressing system that continuously or intermittently applies subatmospheric pressure to the surface of a wound to draw out fluid and promote healing. The SNaP device is a dNPWT device for lower leg wound healing designed for increased portability and ease of use outside of a hospital setting. It is a modification of traditional NPWT devices that uses springs to generate pressure, making it lighter and more user-friendly than traditional devices that rely on electrically powered pumps. This may be a more effective way to promote wound healing in the lower limbs following Mohs surgery for non-melanoma skin cancer.

Read the detailed description

PRIMARY OBJECTIVE:

I. To compare wound healing duration between the two groups, aiming to provide insights into the potential benefits of dNPWT for lower limb wounds in a clinical setting.

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP 1: Patients undergo dNPWT with SNaP device following standard of care (SOC) Mohs surgery and attend follow-up visits with re-application of SNaP device over 30 minutes once a week (QW), as needed until complete wound healing is achieved, for up to 12 weeks. Patients also receive education regarding SNaP device application and informational/educational SNaP device handouts on study.

GROUP 2: Patients undergo SOC wound care with non-adherent dressing following SOC Mohs surgery and attend follow-up visits with non-adherent dressing changes over 30 minutes QW, as needed until complete wound healing is achieved, for up to 12 weeks. Patients also receive education on SOC wound dressing changes on study.

After completion of study intervention, patients are followed up at week 12.

02

Conditions studied

  • Skin Carcinoma
03

In context

Lead sponsor

Jonsson Comprehensive Cancer Center is the lead sponsor of 396 studies on the registry; 67 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 2 (5%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Aged 19 to 79 years
  • Presenting with a lower limb wound following Mohs surgery for non-melanoma skin cancer, designated to heal by secondary intention
  • Wound size less than 13 cm x 13 cm
  • Patient capable of changing the SNAP-therapy system at home

Exclusion criteria

Exclusion Criteria:

  • History of diabetes mellitus
  • History of venous insufficiency
  • History peripheral arterial disease
  • Chronic steroid use (defined as great than 6 weeks) within the last one year
  • History of HIV
  • History of chemotherapy use within the last one year
  • History of smoking exceeding 10 pack-years or current smoker
  • History of stroke
  • History of deep venous thrombosis
  • Active infection
  • Allergy to adhesives
  • Wounds with visible bone, tendon, ligament, nerve
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Group 1 (SNaP device dNPWT)

    Patients undergo dNPWT with SNaP device following SOC Mohs surgery and attend follow-up visits with re-application of SNaP device over 30 minutes QW, as needed until complete wound healing is achieved, for up to 12 weeks. Patients also receive education regarding SNaP device application and informational/educational SNaP device handouts on study.

    Other: Educational Intervention · Other: Electronic Health Record Review · Other: Follow-Up Care · Other: Medical Device Usage and Evaluation · Procedure: Negative Pressure Wound Therapy · Other: Photography · Other: Questionnaire Administration

  • Active comparator
    Group 2 (SOC wound care)

    Patients undergo SOC wound care with non-adherent dressing following SOC Mohs surgery and attend follow-up visits with non-adherent dressing changes over 30 minutes QW, as needed until complete wound healing is achieved, for up to 12 weeks. Patients also receive education on SOC wound dressing changes on study.

    Other: Best Practice · Other: Educational Intervention · Other: Electronic Health Record Review · Other: Follow-Up Care · Other: Photography · Other: Questionnaire Administration

Interventions

  • OtherBest Practice

    Undergo SOC non-adherent dressing wound care

    Also known as: standard of care, standard therapy

  • OtherEducational Intervention

    Receive SNaP education

    Also known as: Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational

  • OtherEducational Intervention

    Receive SOC wound care education

    Also known as: Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational

  • OtherElectronic Health Record Review

    Ancillary studies

  • OtherFollow-Up Care

    Attend SNaP device follow-up visits

  • OtherFollow-Up Care

    Attend SOC wound care follow-up visits

  • OtherMedical Device Usage and Evaluation

    Undergo dNPWT with SNaP device

  • ProcedureNegative Pressure Wound Therapy

    Undergo dNPWT with SNaP device

    Also known as: NPWT, Vacuum-Assisted Wound Closure

  • OtherPhotography

    Ancillary studies

  • OtherQuestionnaire Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Wound healing duration

    Will be defined as the number of days from surgery to complete wound closure (full re-epithelialization), assessed during follow-up visits. Will be analyzed as a time-to-event variable. To compare the time to wound closure between the SNaP Wound Care System (Ultraportable Mechanically Powered Negative Pressure Wound Therapy) (SNaP) device and standard care groups, Kaplan-Meier survival curves will be generated, which will visually illustrate whether the SNaP device accelerates wound healing. The log-rank test will be used to formally assess whether the difference in healing times between the two groups is statistically significant or if any differences observed could have arisen by random chance. Additionally, a Multivariable Cox proportional hazards model will be employed to adjust for potential confounders (e.g., wound size, patient age, and comorbidities).

    Time frame: Up to 12 weeks

Secondary outcomes

  1. Mean time to wound closure

    Among patients who achieve full healing, the mean time to wound closure will be compared between the SNaP device and standard care groups. If the data are normally distributed, an independent two-sample t-test will be used; otherwise, a Mann-Whitney U test will be applied.

    Time frame: Up to 12 weeks

  2. Patient satisfaction

    Patient satisfaction will be assessed using standardized questionnaires and analyzed with t-tests or chi-square tests to compare satisfaction levels between the SNaP device and standard care groups. Effect sizes and 95% confidence intervals will be reported to quantify the magnitude of treatment effects for all secondary outcomes.

    Time frame: At 12 weeks

  3. Wound size progression

    Wound size progression will be monitored over time and analyzed with repeated measures analysis of variance to assess changes within subjects. Effect sizes and 95% confidence intervals will be reported to quantify the magnitude of treatment effects for all secondary outcomes.

    Time frame: Up to 12 weeks

  4. Cosmetic outcomes

    Cosmetic outcomes, particularly scar appearance, will be evaluated using the Patient and Observer Scar and Assessment Scale 3.0, with mixed-effects models applied to account for patient variability and treatment effects. Furthermore, a multivariate analysis will be conducted to examine the combined effects of the SNaP device on both wound closure and cosmetic outcomes while adjusting for confounders such as age, comorbidities, and wound size. Effect sizes and 95% confidence intervals will be reported to quantify the magnitude of treatment effects for all secondary outcomes.

    Time frame: At 12 weeks

07

Study locations

1 site
  • UCLA / Jonsson Comprehensive Cancer Center
    Los Angeles, California 90095, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07032701
Lead sponsor
Jonsson Comprehensive Cancer Center
Responsible party
Sponsor
First posted
Jun 24, 2025
Start date
Dec 2026 (estimated)
Primary completion
Dec 2030 (estimated)
Completion
Jun 2031 (estimated)
Last update
Jul 1, 2026

Study contacts

Jeremy C Davis
principal investigator · UCLA / Jonsson Comprehensive Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion